Top News

Post

Gilead Sciences, Second Genome in Pact For Inflammatory Disease Drug Finds

Gilead Sciences Inc. (GILD) and Second Genome have entered into a four-year partnership aimed at joining forces in biomarker research and discovery of drugs to treat inflammatory bowel disease.
The partnership seeks to identify as many as five new drug candidates for the treatment of inflammatory bowel disease over the next four years, with an option to extend the collaboration for an additional two years.…

S&P 500 
$3,235.06  1.57%  
NASDAQ 100 
$11,023.15  1.72%  
Dow Jones Industrial Average 
$26,628.76  2.12%  
Apple Inc. 
$395.70  3.13%  
Alphabet Inc. 
$1,567.46  1.67%  
MICROSOFT CORP 
189,66 €  0.73%  
Tesla, Inc. 
$1,698.46  9.96%  
Berkshire Hathaway Inc. 
$278,215.94  1.58%  
AbbVie Inc. 
$99.09  2.33%  
Costco Wholesale Corporation 
$327.51  0.39%  
Smartsheet Inc. 
$51.22  -0.39%  
Zai Lab Limited 
$88.22  1.44%  
Western Digital Corporation 
$42.99  1.61%  
NVIDIA Corporation 
$424.14  1.18%  
Gold Aug 20 
$1,813.20  0.63%  
Crude Oil Aug 20 
$40.66  0.27%  
BTC/USD 
$9,285.88  0.10%  
Bitcoin Cash USD 
$235.56  -0.65%  
LTC/USD 
$44.75  0.25%  
ETH/USD 
$242.61  0.20%  
Dogecoin USD 
$0.0033  -8.90%